Display options
Cite
Saha T, Solomon J, Samson AO, et al. Invasion and Metastasis as a Central Hallmark of Breast Cancer. J Clin Med. 2021;10(16)doi: 10.3390/jcm10163498.
Saha, T., Solomon, J., Samson, A. O., & Gil-Henn, H. (2021). Invasion and Metastasis as a Central Hallmark of Breast Cancer. Journal of clinical medicine, 10(16), . https://doi.org/10.3390/jcm10163498
Saha, Trishna, et al. "Invasion and Metastasis as a Central Hallmark of Breast Cancer." Journal of clinical medicine vol. 10,16 (2021). doi: https://doi.org/10.3390/jcm10163498
Saha T, Solomon J, Samson AO, Gil-Henn H. Invasion and Metastasis as a Central Hallmark of Breast Cancer. J Clin Med. 2021 Aug 08;10(16). doi: 10.3390/jcm10163498. PMID: 34441794; PMCID: PMC8396853.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2021 Aug 08;10(16). doi: 10.3390/jcm10163498.

Invasion and Metastasis as a Central Hallmark of Breast Cancer.

Journal of clinical medicine

Trishna Saha, Jonathan Solomon, Abraham O Samson, Hava Gil-Henn

Affiliations

  1. Cell Migration and Invasion Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.
  2. Drug Discovery Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.

PMID: 34441794 PMCID: PMC8396853 DOI: 10.3390/jcm10163498

Abstract

Hanahan and Weinberg introduced the "hallmarks of cancer" and typified essential biological abilities acquired by human cancer. Since then, a growing understanding of hallmark principles associated with breast cancer has assisted knowledge-based therapeutics development; however, despite the rapidly increasing number of targeted therapeutics, enduring disease-free responses for most forms of breast cancer is rare. Invasion and metastasis are the most defining feature of breast cancer malignancy and the leading cause of patient mortality. Hence, we propose a modified hallmarks model adapted to breast cancer, in which invasion and metastasis are shifted to the center of attention, thereby emphasizing it as a potentially superior therapeutic target. Although the scientific community highly appreciates the importance of the invasion and metastasis hallmark, as can be demonstrated by the growing number of publications on breast cancer metastasis, very few clinical trials concentrate on testing anti-metastasis inhibitors and even fewer trials focus on inhibitors for breast cancer metastasis. Here, we discuss the obstacles of applying research on invasion and metastasis therapeutics into the clinic and present current developments that could provide a potential solution to this dilemma.

Keywords: association score; breast cancer; hallmarks; invasion and metastasis; therapeutics

References

  1. Cancer Res. 1993 Aug 15;53(16):3736-40 - PubMed
  2. J Cancer. 2016 Jun 23;7(10):1281-94 - PubMed
  3. J Natl Cancer Inst. 2014 Jan;106(1):djt319 - PubMed
  4. Cells. 2019 Jan 26;8(2): - PubMed
  5. Cancer Discov. 2015 Sep;5(9):932-43 - PubMed
  6. Breast Cancer Res Treat. 2018 Jan;167(2):417-423 - PubMed
  7. Breast Cancer Res. 2001;3(3):146-9 - PubMed
  8. Cancer Discov. 2019 Mar;9(3):354-369 - PubMed
  9. Open Access Maced J Med Sci. 2018 Jun 06;6(6):961-967 - PubMed
  10. Cancers (Basel). 2019 Nov 20;11(12): - PubMed
  11. Lancet. 2014 Feb 8;383(9916):558-63 - PubMed
  12. Anticancer Res. 2003 Sep-Oct;23(5A):3825-35 - PubMed
  13. Int J Cancer. 2011 Apr 15;128(8):1813-21 - PubMed
  14. J Histochem Cytochem. 2012 Mar;60(3):168-73 - PubMed
  15. Mol Cancer. 2018 Feb 19;17(1):34 - PubMed
  16. Breast Cancer Res Treat. 2010 Jun;121(3):777-88 - PubMed
  17. Curr Opin Cell Biol. 2009 Apr;21(2):177-84 - PubMed
  18. Cancers (Basel). 2018 Dec 19;10(12): - PubMed
  19. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  20. Br J Surg. 2021 Jun 22;108(6):622-631 - PubMed
  21. Physiology (Bethesda). 2010 Apr;25(2):85-101 - PubMed
  22. Cell Mol Life Sci. 2016 Apr;73(8):1659-70 - PubMed
  23. Oncogene. 2007 Oct 4;26(45):6469-87 - PubMed
  24. Front Cell Dev Biol. 2021 Mar 22;9:641449 - PubMed
  25. Eur J Cancer. 1993;29A(4):492-7 - PubMed
  26. Mod Pathol. 2010 Feb;23(2):205-12 - PubMed
  27. Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2015-2020 - PubMed
  28. J Cell Sci. 2016 May 1;129(9):1751-8 - PubMed
  29. Acta Histochem. 2016 Jun;118(5):544-52 - PubMed
  30. JAMA. 2017 Jun 20;317(23):2402-2416 - PubMed
  31. West J Med. 1991 Aug;155(2):152-63 - PubMed
  32. Asian Pac J Cancer Prev. 2020 Aug 01;21(8):2243-2250 - PubMed
  33. Arch Pathol Lab Med. 2016 Aug;140(8):806-14 - PubMed
  34. Ann Oncol. 2016 May;27(5):812-8 - PubMed
  35. Clin Cancer Res. 2009 Apr 1;15(7):2433-41 - PubMed
  36. Science. 1989 May 12;244(4905):707-12 - PubMed
  37. Science. 2009 May 22;324(5930):1029-33 - PubMed
  38. J Natl Cancer Inst. 2014 Jun 03;106(8): - PubMed
  39. Cancer Res. 2000 Apr 15;60(8):2155-62 - PubMed
  40. Semin Oncol. 2017 Aug;44(4):273-285 - PubMed
  41. Tumour Biol. 2013 Jun;34(3):1371-80 - PubMed
  42. Mol Cell Biol. 2000 Apr;20(8):2890-901 - PubMed
  43. Cancer Treat Rev. 2020 Jun;86:102017 - PubMed
  44. Cancers (Basel). 2017 Feb 24;9(3): - PubMed
  45. Breast Cancer Res. 2018 Sep 5;20(1):108 - PubMed
  46. Clin Transl Oncol. 2006 Feb;8(2):77-82 - PubMed
  47. J BUON. 2018 Jul-Aug;23(4):862-866 - PubMed
  48. Molecules. 2020 Jan 15;25(2): - PubMed
  49. J Biomed Biotechnol. 2011;2011:284584 - PubMed
  50. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  51. Mol Cancer. 2018 Feb 19;17(1):58 - PubMed
  52. Mol Cancer. 2019 Mar 30;18(1):55 - PubMed
  53. N Engl J Med. 2018 Jun 28;378(26):2458-2460 - PubMed
  54. Oncotarget. 2017 Jan 24;8(4):7175-7180 - PubMed
  55. Oncogene. 2020 Sep;39(36):5811-5824 - PubMed
  56. Cold Spring Harb Perspect Med. 2017 Jan 3;7(1): - PubMed
  57. J Pathol. 2010 Jan;220(2):263-80 - PubMed
  58. Cancer Treat Rev. 2018 Jul;68:102-110 - PubMed
  59. Oncogene. 2013 May 23;32(21):2622-30 - PubMed
  60. Breast Cancer Res. 2012 Oct 31;14(5):R139 - PubMed

Publication Types

Grant support